Hrt Financial LP Argenx Se Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$356.01 - $451.55 $830,927 - $1.05 Million	2,334 New	2,334 $1 Million
Q1 2022 May 16, 2022	SELL	$254.45 - $351.06 $394,397 - $544,143	-1,550 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $421,615 - $547,196	1,550 New	1,550 $542,000
Q2 2021 Aug 16, 2021	SELL	$257.11 - $319.92 $203,116 - $252,736	-790 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$268.3 - $380.31 $211,957 - $300,444	790 New	790 $217,000
Q3 2020 Nov 13, 2020	SELL	$215.51 - $272.51 $194,390 - $245,804	-902 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$127.44 - $232.72 $114,950 - $209,913	902 New	902 $203,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.